Amani Therapeutics
PrivateLast Round
Series A
Mar 23, 2026
Total Funding Raised
$25M
Company Overview
Amani Therapeutics is a biotechnology company developing AM-01, a therapy for serious neuropsychiatric disorders like schizophrenia.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Mental Health, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Amani Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Amani Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 23, 2026 |
Amani Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RTW Investments | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 23, 2026
$25M round completed.
Amani Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Amani Therapeutics's valuation, stock price, and market status.
